GlycA is not a useful biomarker of inflammation in sickle cell disease

International Journal of Laboratory Hematology
Julie K WeismanSwee Lay Thein

Abstract

Sickle cell disease (SCD) is a multisystemic disorder, the pathology being driven by recurrent inflammation particularly during a vaso-occlusive crisis. GlycA, a composite measure of protein glycation, is a sensitive biomarker for disorders associated with vascular inflammation. We determined the utility of GlycA as a biomarker of inflammation in SCD. Stored plasma samples from patients with SCD recruited to two clinical studies were analyzed. One study encompasses 488 patient samples with SCD (HbSS, HbSβ0 and HbSC) at steady state and 52 race-matched, healthy controls. The other study included paired plasma samples during steady state and acute pain crisis from (HbSS) patients with SCD. Plasma GlycA was measured using a proton NMR on the Vantera® Clinical Analyzer. We performed analysis comparing patients with SCD, healthy controls, and paired samples analysis. The mean plasma GlycA level was lower in SCD compared with healthy controls (324.6 ± 70.4 μmol/L vs. 386.3 ± 74.6 μmol/L, P < 0.0001). Within the same patient, mean plasma GlycA during acute pain crisis was lower than steady state, although the difference was not significant (300.5 ± 36.3 μmol/L vs 314.2 ± 34.8 μmol/L, P = 0.020). Plasma GlycA correlated inversely with ...Continue Reading

References

Oct 1, 1992·Journal of Clinical Pathology·N O AkinolaJ Stuart
Aug 4, 1998·European Journal of Haematology·K L BourantasA Mavridis
Feb 11, 1999·The New England Journal of Medicine·C Gabay, I Kushner
Aug 10, 2000·The Journal of Clinical Investigation·O S Platt
Jan 25, 2003·Blood·John D BelcherGregory M Vercellotti
Nov 20, 2004·American Journal of Hematology·Anil PathareDavid Dennison
Jun 30, 2005·Blood·Vikki G NolanMartin H Steinberg
Nov 18, 2006·Clinics in Laboratory Medicine·Elias J JeyarajahJames D Otvos
Dec 7, 2010·Lancet·David C ReesMark T Gladwin
Mar 25, 2011·Journal of Pharmacy & Bioallied Sciences·Sachin JainSania Naseem
Nov 30, 2011·British Journal of Haematology·David C Rees, John S Gibson
Jan 31, 2014·American Journal of Hematology·Hany ElmariahMarilyn J Telen
May 9, 2014·American Journal of Hematology·Andrew W Y ShihMadeleine Verhovsek
Aug 1, 2014·Clinical Biochemistry·Steven P MatyusTimothy J Fischer
Sep 25, 2014·Journal of the American Heart Association·Akintunde O AkinkuolieSamia Mora
Dec 2, 2014·Clinical Biochemistry·Steven P MatyusMargery A Connelly
Jan 7, 2015·Saudi Journal of Biological Sciences·Ghazi A DamanhouriMohammad A Kamal
Mar 18, 2015·Clinical Chemistry·James D OtvosRussell P Tracy
Feb 3, 2016·Chest·Enrico M Novelli, Mark T Gladwin
Sep 23, 2016·Circulation Research·Aditya A JoshiNehal N Mehta
Mar 2, 2017·The Journal of Clinical Investigation·Gregory J KatoMark T Gladwin
Oct 29, 2017·Journal of Translational Medicine·Margery A ConnellyNehal N Mehta

❮ Previous
Next ❯

Citations

Feb 6, 2020·Journal of Clinical Medicine·Rocío Fuertes-MartínNúria Amigó

❮ Previous
Next ❯

Methods Mentioned

BETA
nuclear magnetic resonance
NMR

Clinical Trials Mentioned

NCT00011648
NCT03049475

Software Mentioned

GraphPad Prism
GraphPad

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

© 2022 Meta ULC. All rights reserved